CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 11 enrolled
Drug / intervention
Bupropion +5 moredrug
Likely dose
Bupropion 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02873754
NCT02873754N/ACompleted

Mobile Health Intervention to Help Low-Income Smokers Quit Smoking and Increase Physical Activity

Duke University·interventional·Posted Aug 19, 2016·Updated Jul 13, 2018

In Brief

A clinical study evaluating Cognitive Behavioral Counseling, Mobile Contingency Management, and 4 other interventions for Smoking. Completed, enrolled 11 participants across 1 site.

Detailed Summary

This project proposes to evaluate the feasibility, acceptability, and efficacy of a mobile intervention to target smoking-cessation and increase physical activity among low-income persons. The intervention is called Smoking Treatment and Exercise Program for Underserved Populations (STEP UP).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedAug 19, 2016
Enrollment StartJan 1, 2017
Primary CompletionJul 1, 2017
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 9.9 years ago

Interventions

Cognitive Behavioral Counselingbehavioral

Participants will receive five cognitive-behavioral counseling sessions designed to improve rates of smoking cessation, enhance relapse prevention, and increase physical activity.

Mobile Contingency Managementbehavioral

Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. They will also be asked to wear a fitness tracker to monitor physical activity (i.e., steps walked). Participants are provided monetary reward for videos that suggest smoking abstinence, and for fitness tracker readings that suggest increased physical activity.

Bupropiondrug

All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.

Transdermal nicotine patchdrug

Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant

Nicotine polacrilexdrug

Nicotine gum will be initiated at smoking quit date; 4 mg dose administered as needed

Nicotine lozengedrug

Nicotine lozenge will be initiated at smoking quit date; 4 mg dose administered as needed